文献速递核素与放射性配体治疗肿瘤 PET/CT

多发性内分泌腺瘤病2A型综合征患者的成纤维细胞活化蛋白抑制剂显像与治疗

Fibroblast Activation Protein Inhibitor Imaging and Therapy in a Patient With Multiple Endocrine Neoplasia Type 2A Syndrome.
PubMed 文献 · Clin Nucl Med · 2022-01-01

一例多发性内分泌腺瘤病2A型综合征患者经多次手术和放疗后转诊核医学科寻求诊疗一体化方法。镓-68 DOTATATE PET/CT和碘-131间碘苄胍SPECT/CT的摄取程度不足以使用相应治疗药物;1年后镓-68 FAPI-46 PET/CT显示疾病进展,伴肺、肝、骨和淋巴结转移且镓-68 FAPI-46摄取强烈;随后进行镥-177 Lu-FAPI-46治疗,患者耐受治疗并显示临床改善证据。

要点

  • 多发性内分泌腺瘤病2A型综合征患者在常规核医学诊疗一体化示踪剂摄取不足时,镓-68 FAPI-46 PET/CT可显示强烈摄取。
  • 镓-68 FAPI-46 PET/CT显示疾病进展,伴肺、肝、骨和淋巴结转移。
  • 镥-177 Lu-FAPI-46治疗后患者耐受治疗并显示临床改善证据。

核心结论

  • 镥-177 Lu-FAPI-46治疗在该患者中耐受良好,并显示临床改善证据。

研究设计与样本

  • 一例多发性内分泌腺瘤病2A型综合征患者的病例报告。

主要发现

  • 镓-68 DOTATATE PET/CT和碘-131间碘苄胍SPECT/CT的摄取程度不足以使用相应治疗药物。
  • 1年后镓-68 FAPI-46 PET/CT显示疾病进展,伴肺、肝、骨和淋巴结转移且镓-68 FAPI-46摄取强烈。
  • 镥-177 Lu-FAPI-46治疗后患者耐受治疗并显示临床改善证据。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A patient with multiple endocrine neoplasia type 2A syndrome who had exhausted several surgeries and radiotherapy was referred to nuclear medicine department for theranostic approaches. [68Ga]-DOTATATE PET/CT and [131I]I-mIBG SPECT/CT were performed, but the degree of uptake was insufficient for using the treatment companion of these tracers. Finally, 1 year later, [68Ga]-FAPI-46 PET/CT showed progressive disease with metastases to the lung, liver, bone, and lymph nodes with intense [68Ga]-FAPI-46 uptake. Treatment with [177Lu]Lu-FAPI-46 was done, and the patient tolerated treatment and showed evidence of clinical improvement following therapy.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Barashki S, Divband G, Askari E, et al. Fibroblast Activation Protein Inhibitor Imaging and Therapy in a Patient With Multiple Endocrine Neoplasia Type 2A Syndrome. Clin Nucl Med. 2022. PMID: 35067538. doi:10.1097/RLU.0000000000004051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。